Skip to main content

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group StudyComparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration ofFremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine inPediatric Patients 6 to 17 Years of Age

  • Protocol code: TV48125-CNS-30082
  • EudraCT code: 2019-002058-33
  • Research group: Headache and Neurological Pain
  • Service: Neurology
  • Principal investigator:  Pozo Rosich, Patricia
  • Pathology: Malalties del sistema nerviós
  • Phase: Fase III
  • Status: Recruiting volunteers